13F Filings/TYBOURNE CAPITAL MANAGEMENT HK LTD

TYBOURNE CAPITAL MANAGEMENT HK LTD

Hedge FundCIK0001553936LocationHONG KONG, Hong Kong XXXXX, United States

Long U.S. equity positions disclosed to the SEC on Form 13F-HR.

Latest filingQ3 2025Quarter ended30 Sept 2025Filed6 Nov 2025
Firm profile · Form ADV
SEC adviser registration
CRD
164723 · 802-76945
Portfolio Turnover
18%
Of book traded, QoQ
Positions
4
Long U.S. equities
Top 10 Concentration
100%
Of reported value
QoQ Change
$-3.6M
Value change
Assets under management
Form ADV RAUM · client mix · 13F over time
13F AUM over time
$31M
Q3 ’25 · 13F AUM
▼ 95%
50 quarters
Sector Breakdown
Latest filing
Health Care100.0% · $30.9M
Reported Holdings
Q3 2025 · sign up free for past quarters
↗
★ Position spotlightTSHATAYSHA GENE THERAPIES INC (TSHA US) · 39.1% of book
🔒
See how this position changed across every quarter
Multi-quarter 13F position history — shares held, buys & sells, and price over time — is a Pro feature. The latest snapshot below stays free.
Security⇅Shares⇅Market Value▼Est. Cost⇅Last Px⇅Est. Return⇅% Portfolio⇅Δ Shares⇅Action⇅
TAYSHA GENE THERAPIES INC (TSHA US)
TSHA· Health Care
3.70MSH$12.1M~$3.27$6.34▲93.9%39.1%▼ 9.6%Reduced
FORTE BIOSCIENCES INC (FBRX US)
FBRX· Health Care
787KSH$11.8M~$15.00$21.03▲40.2%38.1%—Unchanged
ALUMIS INC (ALMS US)
ALMS· Health Care
1.40MSH$5.6M~$3.99$26.40▲561.7%18.0%—Unchanged
ZENTALIS PHARMACEUTICALS INC (ZNTL US)
ZNTL· Health Care
961KSH$1.5M~$1.51$4.04▲167.5%4.7%▼ 35.0%Reduced
TSHATAYSHA GENE THERAPIES INC (TSHA US)Reduced
$12.1M· 39.1%· 3.70M SH· ▼ 9.6%· cost $3.27· last $6.34· ▲93.9%
Health Care · COM SHS · SOLE
FBRXFORTE BIOSCIENCES INC (FBRX US)Unchanged
$11.8M· 38.1%· 787K SH· —· cost $15.00· last $21.03· ▲40.2%
Health Care · COM NEW · SOLE
ALMSALUMIS INC (ALMS US)Unchanged
$5.6M· 18.0%· 1.40M SH· —· cost $3.99· last $26.40· ▲561.7%
Health Care · COM · SOLE
ZNTLZENTALIS PHARMACEUTICALS INC (ZNTL US)Reduced
$1.5M· 4.7%· 961K SH· ▼ 35.0%· cost $1.51· last $4.04· ▲167.5%
Health Care · COM · SOLE
← All 13F filings